CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neubase Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neubase Therapeutics Inc
350 Technology Drive
Phone: (412) 763-3350p:412 763-3350 PITTSBURGH, PA  15219  United States Ticker: NBSENBSE

On 3/5/2024, the Board of Neubase Therapeutics Inc unanimously approved the Company's voluntary Plan of Liquidation and Dissolution.

Business Summary
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20239/30/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Dov A.Goldstein 55 10/11/2022 7/12/2019
Interim Chief Executive Officer, Chief Financial Officer Todd P.Branning 53 1/16/2024 1/10/2022
Director Dietrich A.Stephan 53 1/16/2024 7/1/2019
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SKS OCULAR LLC 5871 OBERLIN DR STE 150 SAN DIEGO CA

Business Names
Business Name
NBSE
NeuBase Corporation
Ohr Opco, Inc.
Ohr Pharma, LLC
OHRP
SKS Ocular LLC

General Information
Number of Employees: 37 (As of 9/30/2022)
Outstanding Shares: 3,729,206 (As of 11/6/2023)
Stock Exchange: NASD
Federal Tax Id: 043648721
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024